$SUNPHARMA Sun Pharma Q4 FY26 result

Sun Pharma Q4 FY26 result (announced on 22 May 2026) 📊 Financial Performance Net Profit: ₹2,714 crore (▲ 26.2% YoY) Revenue: ₹14,559.8 crore (▲ 13.6% YoY) EBITDA: ₹3,774 crore (▲ 16.5% YoY) EBITDA Margin: 25.9% (vs 25.2% last year) 🌍 Business Highlights India Formulations: ₹4,826 crore (▲ 14.8% YoY) US Business: Crossed $1 billion in annual revenues, driven by specialty products. Global Specialty Medicines: Strong growth in Ilumya, Winlevi, and Cequa. R&D Spend: ₹1,013 crore (6.9% of sales). 💰 Dividend Declared ₹5/share final dividend, taking total FY26 dividend to ₹16/share. 🔎 Key Takeaways Sun Pharma maintained its No.1 position in the Indian pharma market. Specialty portfolio continues to be the growth driver globally. Strong cash generation supports dividend payout and future investments.